BK Titanji #ILookLikeAScientist
Thu Apr 01
Physician(MD)-Scientist(PhD),She/Her, EmoryID🇺🇲 via 🇨🇲/(LSHTM & UCL)🇬🇧. Loves viruses, TED talks & Global Health. Blogger at https://t.co/MQz4bQ5ULV
🗞 Release with great💉 news:
@pfizer #covid19💉 still highly protective at 6month (91%).
📌Small RCT in 🇿🇦 shows it has good 🛡vs. B.1351 VOC. Only 9 cases of 🤧🤒 #COVID19 in the small 800 individuals.
Can this vaccine be accessible to 🇿🇦🇧🇷 ASAP?
Increasing evidence that Pfizer is v good at preventing transmission while AZ is being promoted as only preventing progression to more serious illness. Surely we must greatly increase supply of Pfizer/Moderna/Novavax and rethink to whom AZ is being administered? twitter.com/mja_editor/sta…
Professor of Infectious Diseases, University of Cape Town. Co-chair South African Antibiotic Stewardship Programme. Views are my own. RTs are not endorsements
Small numbers  so far in 🇿🇦, but #Pfizer vaccine looking good against B.1.351 strain with no cases in vaccinated arm vs 9 in placebo. Overall, duration protection now proven (at least) 6 months and counting @ShabirMadh @FrancoisVenter3 cnn.com/2021/04/01/hea…
Infectious disease MD (also CCM & EM)working on pandemic policy, emerging infections, preventing bioterror https://t.co/1yNUzIwLQJ
“In South Africa, where the B.1.351 lineage is prevalent and 800 participants were enrolled, nine cases of COVID-19 were observed, all in the placebo group, indicating vaccine efficacy of 100%” — major news
Epidemiologist & Health Economist. Health Policy & Justice. Senior Fellow, FAS. Former 16 yrs @Harvard. @JohnsHopkins & @HarvardEPI alum. COVID updates Jan’20-
Good news—6 months results—Pfizer vaccine remains more than 91% effective against disease with any symptoms for six months. And it appeared to be so far good against the worrying #B1351 variant from South Africa in limited data so far. Thread 🧵 #COVID19
2) "The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA)," Pfizer and BioNTech said”
3) "These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA," Albert Bourla, Pfizer's CEO, said in a statement. A BLA is an application for full approval—currently it has EUA.
4) “In South Africa, where the B.1.351 lineage is prevalent and 800 participants were enrolled, nine cases of COVID-19 were observed, all in the placebo group, indicating vaccine efficacy of ~100%”
My take — this is extremely early. I doubt it will stay like that. But hopeful.
5) "Vaccine safety has now been evaluated in more than 44,000 participants aged 16 years and older with more than 12,000 vaccinated participants having at least six months of follow-up after their second dose."
Physician, scientist, epidemiologist, global health advocate, former @CDCgov, current @SabinVaccine vice-president, but tweets are my own.
SOBRE A VACINA Q O PR RECUSOU
Continuação da Fase 3 mostra que 6 meses depois a proteção se mantém, mesmo com novas variantes.
- eficácia de 91% contra caso sintomático, incluindo para variante da África do Sul
- eficácia de 95,3% contra casos graves cnn.com/2021/04/01/hea…
Great news from Pfizer this morning! Their #covid19 #vaccine is efficacious for at least 6 months. Appears to work very well against B.1.351 variant (strain dominant in South Africa). google.com/amp/s/amp.cnn.…
These findings bode well for the vaccine's long-term protection. Unless variants with worse immune evasion emerge (a big if, given lack of virus containment), it's possible that we may see a durable, on-demand immune response for at least 2-3 years pic.twitter.com/Q7iDXw08bK